目的:回顾所有报告在COVID-19疫苗接种后出现白点综合征的研究。
方法:我们的方案在PROSPERO上登记[登记号:CRD42023426012]。我们搜索了五个不同的数据库包括PubMed,Scopus,WebofScience,谷歌学者,和科学直接到2023年5月。包括所有报道COVID-19疫苗后出现白点综合征的研究。所有统计测试均以95%的置信区间和5%的误差范围进行。小于0.05的p值被认为是统计学上显著的。纳入研究的方法学质量使用IHE质量评估清单进行案例系列研究和JBI关键评估清单进行案例报告。
结果:纳入了涉及71名受试者的50项研究。多发性消逝白点综合征(MEWDS)是最常见的疾病(n=25,35.2%),其次是急性黄斑神经视网膜病变(AMN)(n=22,31.0%)和急性后部多灶性胎盘色素上皮病变(APMPPE)(n=4,5.6%)。他们大多是单方面的(n=50,70.4%)。表现为视力模糊(n=26,36.6%),腹侧暗点(n=19,26.8%),视野干扰,和光视(n=7,9.9%)。平均随访时间为10.15±14.04周。19名受试者(29.69%)接受了类固醇治疗,报告的改善率为68.4%。11名受试者(17.19%)仅通过观察进行管理,报告完全恢复和改善。
结论:白点综合征是非常罕见的实体。我们的发现强调了COVID-19疫苗与白点综合征的发生之间的可能关联。然而,应实施高质量的大型研究以证实这些发现.
OBJECTIVE: To review all studies reporting the onset of white dot syndromes following COVID-19 vaccines.
METHODS: Our protocol was registered prospectively on PROSPERO [registration number: CRD42023426012]. We searched five different databases including PubMed, Scopus, Web of Science, Google Scholar, and Science Direct up to May 2023. All the studies that reported the occurrence of white dot syndrome following COVID-19 vaccines were included. All statistical tests were conducted with a 95% confidence interval and a 5% error margin. A p value of less than 0.05 was considered statistically significant. The methodological quality of included studies was performed using the IHE Quality Appraisal Checklist for Case Series studies and JBI Critical Appraisal Checklist for Case Reports.
RESULTS: Fifty studies involving seventy-one subjects were included. Multiple evanescent white dot syndrome (MEWDS) was the most common disease (n = 25, 35.2% %), followed by acute macular neuroretinopathy (AMN) (n = 22, 31.0%) and acute posterior multifocal placoid pigment epitheliopathy (APMPPE) (n = 4, 5.6%). They were mostly unilateral (n = 50, 70.4%). The presenting symptoms were blurred vision (n = 26, 36.6%), paracentral scotoma (n = 19, 26.8%), visual field disturbance, and photopsia (n = 7, 9.9%). The mean duration for follow-up was 10.15 ± 14.04 weeks. Nineteen subjects (29.69%) received steroids with improvement reported in 68.4%. Eleven subjects (17.19%) were managed by observation only with reported full recovery and improvement.
CONCLUSIONS: White dot syndromes are very rare entities. Our findings highlight a possible association between COVID-19 vaccines and the occurrence of white dot syndromes. However, larger studies with good quality should be implemented to confirm these findings.